【摘要】 目的:探讨替格瑞洛对不稳定性心绞痛患者经皮冠状动脉介入术后抗血小板治疗的临床价值。方法:选择2013年8月—2014年2月收治的不稳定性心绞痛经皮冠状动脉介入治疗的患者150例,采用随机数字表法分为2组,对照组(75例)患者口服氯吡格雷,观察组(75例)患者口服替格瑞洛。对比观察2组患者的临床疗效及安全性。结果:用药1周后,观察组患者血小板凝聚率为(40.3±7.5)%,明显低于对照组的(56.2±7.8)%,差异有统计学意义(P<0.05);随访12个月,观察组患者主要心血管事件发生率为5.3%(4/75),明显低于对照组的16.0%(12/75),差异有统计学意义(P<0.05);2组患者均未发生严重出血事件及支架内血栓事件。结论:不稳定性心绞痛患者行经皮冠状动脉介入治疗后使用替格瑞洛,替格瑞洛可发挥较氯吡格雷更强的抗血小板聚集作用,且用药更安全。更多还原

【Abstract】 OBJECTIVE: To explore the clinical value of ticagrelor as antiplatelet therapy in patients with unstable angina pectoris after undergoing percutaneous coronary interventions( PCI). METHODS: From Aug. 2013 to Feb.2014,a total of 150 patients with unstable angina undergoing PCI were randomly assigned to receive either clopidogrel( control group) or ticagrelor( observation group) of 75 cases in each group. The clinical efficacy and safety in the 2groups of patients were recorded. RESULTS: After treatment of 1 week,the platelet aggregation rate in the observation group was significantly lower than in the control group [( 40. 3 ± 7. 5) % vs.( 56. 2 ± 7. 8) %; P < 0. 05 ]; at 12 months of follow-up,the incidence of MACE( major adverse cardiovascular events) in the observation group was significantly lower than in the control group [5. 3%( 4 /75) vs. 16. 0%( 12 /75); P < 0. 05 ]; neither group presented with serious bleeding events and stent thrombosis. CONCLUSIONS: Use of ticagrelor in patients with angina pectoris after PCI may exhibited a better antiplatelet aggregation action and better drug safety.更多还原